相关实验视频
Updated: Jun 23, 2026
07:54
Cholesterol Efflux Assay
Published on: March 6, 2012
减少ABCA1介导的胆固醇外流和加速动脉样硬化在缺乏宏细胞衍生ACAT1的非脂蛋白E缺陷小鼠中
Yan Ru Su1, Dwayne E Dove, Amy S Major
1Atherosclerosis Research Unit, Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tenn 37232-6300, USA. Yan.Ru.Su@vanderbilt.edu
Circulation
|April 27, 2005
概括
巨细胞的ACAT1删除在apoE-/-小鼠中加速动脉样硬化,除非巨细胞的apoE纠正胆固醇水平. 缺少ACAT1会影响胆固醇排放,增加炎症和亡.
科学领域:
- 心血管生物学 心血管生物学
- 动脉样硬化研究 动脉样硬化研究
- 巨细胞生物学 巨细胞生物学
背景情况:
- 巨细胞ACAT1和apoE调节胆固醇稳态和泡细胞的形成.
- 在超脂血症小鼠中,ACAT1或apoE删除会增加动脉样硬化.
- 这项研究研究了ACAT1删除对apoE缺乏小鼠的动脉动脉生成的影响.
研究的目的:
- 确定巨细胞ACAT1在apoE缺乏小鼠的动脉动脉生成中的作用.
- 为了评估ACAT1删除与或没有巨细胞的apoE恢复的影响.
- 阐明ACAT1对胆固醇代谢和炎症的影响背后的机制.
主要方法:
- 骨髓移植用于制造具有四种巨基因型 (野生型,ACAT1-/-, apoE-/-,和2KO) 的apoE-/-小鼠.
- 血胆固醇,动脉样硬化和大动脉亡的分析.
- 在巨细胞中评估胆固醇流向apoA-I和ABCA1表达.
- 在ACAT1-/-巨细胞中基因表达的微阵列分析.
主要成果:
- 巨细胞ACAT1缺乏在巨细胞apoE缺失时,在apoE-/-小鼠中加速动脉样硬化.
- 血胆固醇正常化和ACAT1缺乏在巨 ApoE 存在时没有显著影响.
- 缺少ACAT1减少了胆固醇流向apoA-I,并改变了ABCA1的表达,增加了促炎和促原基因.
结论:
- 巨细胞ACAT1缺乏会在高胆固醇血的apoE-/-小鼠中加剧动脉样硬化,但这是通过巨细胞apoE表达减轻的.
- 删除ACAT1损害了ABCA1介导的胆固醇外流,独立于apoE表达.
- 缺少ACAT1会影响巨细胞膜的稳定性,亡和炎症反应,导致动脉样硬化加速.
相关概念视频
01:38Inflammation
Overview
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...